Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical Trial
暂无分享,去创建一个
Jamie L. Adams | L. Seeberger | H. D. Rosas | K. Marder | S. Hersch | J. Long | R. Conwit | C. Lungu | J. Quinn | S. Factor | P. O'Suilleabhain | C. Singer | J. Perlmutter | S. Perlman | M. Cudkowicz | M. Brownstein | J. Shefner | S. Kostyk | P. Hedera | R. Dubinsky | C. Coffey | E. Most | N. Simon | F. Marshall | K. Anderson | C. Gray | Jon W. Yankey | V. Suski | R. Chuang | A. Duker | M. Barrett | M. Quigg | D. Bega | H. Maibach | D. Ecklund | E. Damiano | Debra E Itzkowitz | Shi-fang Lu | Marianne Chase | Andrew McGarry | B. Thornell | Catherine Gladden | Michele L. Costigan | Amy M Chesire | Paul Deritis | K. M. Lowen | A. Hiller | Kellie Keith | C. Gruenwald | A. Molloy | Cara Jacob | Elaine Sperin | Zsazsa R Brown | V. Sung | M. Benge | Allison M. Daley | P. Conlon | Stephanie Lowenhaupt | Brenton A Wright | Elaine Most | G. Schwartz | J. Lamb | J. Moran | J. R. Singleton | M. Zorn | Paola Wall | C. Drazinic | A. McGarry | Marianne K Chase | Debra E. Itzkowitz